First biosimilars prequalified after full assessment
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
On 05 February 2021, Gilead Sciences Ltd.
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Velpatasvir (WHOAPI-353) manufactured by Mylan Laboratories Ltd has been prequalified by the WHO Prequalification Unit - Medicines Team (PQT/MED) under its API prequalification procedure.
On 13 November 2020, WHO listed the nOPV2 vaccine (Bio Farma, Indonesi
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Remdesivir removed from the PQT Invitations for Expression of Interest (EOIs) (FPPs and APIs).
See link for recent World Health Organization (WHO) recommendations:
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
New Invitation for Expression of Interest (EOI) to manufacturers of antimalarial medicines published
New Invitation for Expression of Interest (EOI) for HIV/AIDS medicines published
The DRAFT TSS 7 - Annex 1 Qualification of usability for self-testing with rapid diagnostic tests to detect hepatitis C antibody is now avaiable for public comments.
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit - Medicines Assessment Team (PQT/MED) has been in contact with Sanofi regarding the presence of 1-cyclopentyl-4-nitrosopiperazine (CPNP) in their tuberculosis treatment -
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
WHO Prequalification Unit (PQT) added the below newproducts to its prequalified list:
Nitrosamine impurities have been identified in rifapentine and rifampicin products.